Olaparib (prostate cancer) – Second Addendum to Commission A23-03

Report documents

1. Addendum

   Olaparib (prostate cancer) – Second Addendum to Commission A23-03

   published on

   06.07.2023

   Document type

   PDF document, 298 kB, DE, not accessible

   Download file : Addendum (PDF document, 298 kB, DE, not accessible)

Additional information

Project details

Project no.

G23-13

Commission

Commission awarded on 23.05.2023 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

Connected Projects

1. Dossier assessment

   Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V

   Project no.

   A23-03

   Last updated

   06.07.2023

   Status: Commission completed